High-Sensitivity C-Reactive Protein as an Associate of Clinical Subsets and Organ Damage in Systemic Lupus Erythematosus

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 1, 2008, Pages 41-54

  Lee, Shin Seok ^a   Singh, Sukhminder ^a   Link, Kimberly ^a   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C reactive protein; cardiovascular risk factors; inflammation; systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; DNA ANTIBODY; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LUPUS ANTICOAGULANT; PREDNISONE;

ADULT; ANEMIA; ARTICLE; BODY MASS; COHORT ANALYSIS; COLITIS; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG USE; EDUCATIONAL STATUS; ETHNICITY; FEMALE; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; GENDER; HEART MURMUR; HEPATOMEGALY; HUMAN; INFLAMMATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; MYOCARDITIS; ORGAN INJURY; PANCREATITIS; PLEURISY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SENSITIVITY ANALYSIS; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS;

ADULT; AUTOANTIBODIES; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 48949118186     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.09.005     Document Type: Article

References (69)

1. Marnell L., Mold C., and Du Clos T.W. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 117 (2005) 104-111
2. Pereira Da Silva J.A., Elkon K.B., Hughes G.R., Dyck R.F., and Pepys M.B. C-reactive protein levels in systemic lupus erythematosus: a classification criterion?. Arthritis Rheum 23 (1980) 770-771
3. Becker G.J., Waldburger M., Hughes G.R., and Pepys M.B. Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 39 (1980) 50-52
4. Honig S., Gorevic P., and Weissmann G. C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 20 (1977) 1065-1070
5. Williams Jr. R.C., Harmon M.E., Burlingame R., and Du Clos T.W. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 32 (2005) 454-461
6. al-Mekaimi A., Malaviya A.N., Serebour F., Umamaheswaran I., Kumar R., al-Saeid K., et al. Serological characteristics of systemic lupus erythematosus from a hospital-based rheumatology clinic in Kuwait. Lupus 6 (1997) 668-674
7. Morrow W.J., Isenberg D.A., Parry H.F., and Snaith M.L. C-reactive protein in sera from patients with systemic lupus erythematosus. J Rheumatol 8 (1981) 599-604
8. Spronk P.E., ter Borg E.J., and Kallenberg C.G. Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response?. Ann Rheum Dis 51 (1992) 358-361
9. Mochizuki T., Aotsuka S., and Satoh T. Clinical and laboratory features of lupus patients with complicating pulmonary disease. Respir Med 93 (1999) 95-101
10. Zuniga R., Markowitz G.S., Arkachaisri T., Imperatore E.A., D'Agati V.D., and Salmon J.E. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and FCgamma receptor type IIA alleles. Arthritis Rheum 48 (2003) 460-470
11. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 26 (2000) 199-213 v
12. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
13. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42 (1999) 599-608
14. Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Urowitz M., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39 (1996) 363-369
15. Roberts W.L., Moulton L., Law T.C., Farrow G., Cooper-Anderson M., Savory J., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47 (2001) 418-425
16. To C.H., and Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?. Arthritis Rheum 52 (2005) 4003-4010
17. Petri M., Rheinschmidt M., Whiting-O'Keefe Q., Hellmann D., and Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 106 (1987) 524-531
18. Brandt J.T., Barna L.K., and Triplett D.A. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 74 (1995) 1597-1603
19. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
20. Khera A., McGuire D.K., Murphy S.A., Stanek H.G., Das S.R., Vongpatanasin W., et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46 (2005) 464-469
21. Albert M.A., Glynn R.J., Buring J., and Ridker P.M. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 93 (2004) 1238-1242
22. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., and Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282 (1999) 2131-2135
23. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
24. van Rooijen M., Hansson L.O., Frostegard J., Silveira A., Hamsten A., and Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 4 (2006) 77-82
25. Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100 (1999) 717-722
26. Zonana-Nacach A., Barr S.G., Magder L.S., and Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43 (2000) 1801-1808
27. ter Borg E.J., Horst G., Limburg P.C., van Rijswijk M.H., and Kallenberg C.G. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 17 (1990) 1642-1648
28. Jonsson H., Nived O., and Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 68 (1989) 141-150
29. Sturfelt G., and Sjoholm A.G. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 75 (1984) 75-83
30. Kolb M., Margetts P.J., Anthony D.C., Pitossi F., and Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 107 (2001) 1529-1536
31. Sime P.J., Marr R.A., Gauldie D., Xing Z., Hewlett B.R., Graham F.L., et al. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol 153 (1998) 825-832
32. Miyata M., Sakuma F., Yoshimura A., Ishikawa H., Nishimaki T., and Kasukawa R. Pulmonary hypertension in rats. 1. Role of bromodeoxyuridine-positive mononuclear cells and alveolar macrophages. Int Arch Allergy Immunol 108 (1995) 281-286
33. Voelkel N.F., Tuder R.M., Bridges J., and Arend W.P. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 11 (1994) 664-675
34. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., and Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106 (2002) 1439-1441
35. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W., Li R.K., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105 (2002) 1890-1896
36. Magro C.M., Waldman W.J., Knight D.A., Allen J.N., Nadasdy T., Frambach G.E., et al. Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol 67 (2006) 284-297
37. Kondoh Y., Taniguchi H., Kawabata Y., Yokoi T., Suzuki K., and Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103 (1993) 1808-1812
38. Joppa P., Petrasova D., Stancak B., and Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 130 (2006) 326-333
39. Elstein D., Nir A., Klutstein M., Rudensky B., and Zimran A. C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease. Blood Cells Mol Dis 34 (2005) 201-205
40. Roldan C.A., Shively B.K., and Crawford M.H. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 335 (1996) 1424-1430
41. Galve E., Candell-Riera J., Pigrau C., Permanyer-Miralda G., Garcia-Del-Castillo H., and Soler-Soler J. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 319 (1988) 817-823
42. Doria A., Iaccarino L., Sarzi-Puttini P., Atzeni F., Turriel M., and Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus 14 (2005) 683-686
43. Kao A.H., Sabatine J.M., and Manzi S. Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 15 (2003) 519-527
44. Tomita M., Dragoman M., Worcester H., Conran P., and Santoro T.J. Proinflammatory cytokine genes are constitutively overexpressed in the heart in experimental systemic lupus erythematosus: a brief communication. Exp Biol Med (Maywood) 229 (2004) 971-976
45. Mandell B.F. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 17 (1987) 126-141
46. Weich H.S., Burgess L.J., Reuter H., Brice E.A., and Doubell A.F. Large pericardial effusions due to systemic lupus erythematosus: a report of eight cases. Lupus 14 (2005) 450-457
47. Kaneko K., Kanda T., Hasegawa A., Suzuki T., Kobayashi I., and Nagai R. C-reactive protein as a prognostic marker in lymphocytic myocarditis. Jpn Heart J 41 (2000) 41-47
48. Maksimowicz-McKinnon K., and Mandell B.F. Understanding valvular heart disease in patients with systemic autoimmune diseases. Cleve Clin J Med 71 (2004) 881-885
49. Sallmann S., Juttler E., Prinz S., Petersen N., Knopf U., Weiser T., et al. Induction of interleukin-6 by depolarization of neurons. J Neurosci 20 (2000) 8637-8642
50. Jankowsky J.L., Derrick B.E., and Patterson P.H. Cytokine responses to LTP induction in the rat hippocampus: a comparison of in vitro and in vivo techniques. Learn Mem 7 (2000) 400-412
51. Vezzani A., Conti M., De Luigi A., Ravizza T., Moneta D., Marchesi F., et al. Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 19 (1999) 5054-5065
52. Peltola J., Hurme M., Miettinen A., and Keranen T. Elevated levels of interleukin-6 may occur in cerebrospinal fluid from patients with recent epileptic seizures. Epilepsy Res 31 (1998) 129-133
53. Peltola J., Laaksonen J., Haapala A.M., Hurme M., Rainesalo S., and Keranen T. Indicators of inflammation after recent tonic-clonic epileptic seizures correlate with plasma interleukin-6 levels. Seizure 11 (2002) 44-46
54. Tsai C.Y., Wu T.H., Tsai S.T., Chen K.H., Thajeb P., Lin W.M., et al. Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. Scand J Rheumatol 23 (1994) 57-63
55. Hirohata S., Tanimoto K., and Ito K. Elevation of cerebrospinal fluid interleukin-6 activity in patients with vasculitides and central nervous system involvement. Clin Immunol Immunopathol 66 (1993) 225-229
56. Alcocer-Varela J., Aleman-Hoey D., and Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1 (1992) 111-117
57. Svenungsson E., Andersson M., Brundin L., van Vollenhoven R., Khademi M., Tarkowski A., et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 60 (2001) 372-379
58. Trysberg E., Nylen K., Rosengren L.E., and Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 48 (2003) 2881-2887
59. Trysberg E., Carlsten H., and Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 9 (2000) 498-503
60. Houtman P.M., and Hofstra S.S. Lupus peritonitis presented as vague abdominal complaints in a SLE patient. Neth J Med 40 (1992) 232-235
61. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276 (2001) 7806-7810
62. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., and Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 (2003) 2461-2463
63. Nicolas G., Bennoun M., Porteu A., Mativet S., Beaumont C., Grandchamp B., et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci USA 99 (2002) 4596-4601
64. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98 (2001) 8780-8785
65. Ortega O., Rodriguez I., Gallar P., Carreno A., Ortiz M., Espejo B., et al. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant 17 (2002) 1105-1109
66. Zimmermann J., Herrlinger S., Pruy A., Metzger T., and Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999) 648-658
67. Becker-Merok A., and Nossent H.C. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 33 (2006) 1570-1577
68. Stoll T., Sutcliffe N., Mach J., Klaghofer R., and Isenberg D.A. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology (Oxford) 43 (2004) 1039-1044
69. Sailer T., Vormittag R., Pabinger I., Vukovich T., Lehr S., Quehenberger P., et al. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol 32 (2005) 462-468